ZA201408893B - Method for inducing udp-glucuronosyltransferase activity using pterostilbene - Google Patents

Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Info

Publication number
ZA201408893B
ZA201408893B ZA2014/08893A ZA201408893A ZA201408893B ZA 201408893 B ZA201408893 B ZA 201408893B ZA 2014/08893 A ZA2014/08893 A ZA 2014/08893A ZA 201408893 A ZA201408893 A ZA 201408893A ZA 201408893 B ZA201408893 B ZA 201408893B
Authority
ZA
South Africa
Prior art keywords
pterostilbene
udp
inducing
glucuronosyltransferase activity
glucuronosyltransferase
Prior art date
Application number
ZA2014/08893A
Other languages
English (en)
Inventor
Dellinger Ryan
Bartos Jeremy
Original Assignee
Univ California
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Chromadex Inc filed Critical Univ California
Publication of ZA201408893B publication Critical patent/ZA201408893B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA2014/08893A 2012-05-08 2014-12-04 Method for inducing udp-glucuronosyltransferase activity using pterostilbene ZA201408893B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/466,827 US8841350B2 (en) 2011-05-11 2012-05-08 Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
PCT/US2012/064993 WO2013169291A2 (en) 2012-05-08 2012-11-14 Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Publications (1)

Publication Number Publication Date
ZA201408893B true ZA201408893B (en) 2016-08-31

Family

ID=47142275

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/08893A ZA201408893B (en) 2012-05-08 2014-12-04 Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Country Status (12)

Country Link
US (2) US8841350B2 (enExample)
EP (1) EP2846785A4 (enExample)
JP (1) JP2015523963A (enExample)
KR (1) KR20150027081A (enExample)
CN (1) CN104768543A (enExample)
AU (1) AU2012379655B2 (enExample)
BR (1) BR112014027646A2 (enExample)
CA (1) CA2872623A1 (enExample)
IN (1) IN2014DN09990A (enExample)
MX (1) MX2014013503A (enExample)
WO (1) WO2013169291A2 (enExample)
ZA (1) ZA201408893B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004304B1 (pt) * 2014-09-04 2020-12-08 The Regents Of The University Of California uso de pteroestilbeno para prepação de composições tópicas no tratamento de perda de função de barreira na pele induzidas por uv
WO2016037007A1 (en) * 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
CN107849083A (zh) 2015-06-10 2018-03-27 益力舒健康公司 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法
US12134956B2 (en) 2022-10-11 2024-11-05 Halliburton Energy Services, Inc. Liner hanger system
US12398624B2 (en) 2023-07-11 2025-08-26 Halliburton Energy Services, Inc. Self-energizing seal for expandable liner hanger
US12509957B1 (en) 2024-09-16 2025-12-30 Halliburton Energy Services, Inc. Partially bonded seals for well systems

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623724B2 (en) * 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
DE10161253A1 (de) 2001-12-13 2003-06-26 Dragoco Gerberding Co Ag Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren
FR2869229B1 (fr) 2004-04-26 2006-08-25 Sederma Soc Par Actions Simpli Utilisation d'un inducteur des ugt par voie topique
ES2246165B1 (es) 2004-07-20 2006-12-01 Universitat De Valencia Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
US8426369B2 (en) 2006-12-07 2013-04-23 Rutgers, The State University Of New Jersey Prevention and treatment of colon cancer
US8509879B2 (en) 2007-11-06 2013-08-13 The Regents Of The University Of California Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging
US20090175984A1 (en) * 2008-01-08 2009-07-09 David Rubin Method and compositions for preserving wine
US20090324740A1 (en) 2008-06-13 2009-12-31 Albritton Iv Ford D Novel nasal spray
US20100240767A1 (en) 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
EP2445488B1 (en) 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
WO2011042482A1 (en) * 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
EP2322159A1 (en) 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US8513236B2 (en) * 2010-02-03 2013-08-20 Laurus Labs Private Limited Pterostilbene cocrystals
US8883218B2 (en) * 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
CA2826034A1 (en) 2011-01-28 2012-08-02 University Of Kentucky Research Foundation Stilbene analogs and methods of treating cancer
JP6155191B2 (ja) * 2011-10-02 2017-06-28 キユーピー株式会社 RNA干渉によるmRNA発現の抑制を促進する促進剤およびその用途

Also Published As

Publication number Publication date
IN2014DN09990A (enExample) 2015-08-14
US10039725B2 (en) 2018-08-07
AU2012379655B2 (en) 2018-01-18
US8841350B2 (en) 2014-09-23
WO2013169291A2 (en) 2013-11-14
CN104768543A (zh) 2015-07-08
EP2846785A2 (en) 2015-03-18
EP2846785A4 (en) 2016-06-15
JP2015523963A (ja) 2015-08-20
US20120289605A1 (en) 2012-11-15
BR112014027646A2 (pt) 2017-06-27
AU2012379655A1 (en) 2014-11-20
US20150011650A1 (en) 2015-01-08
WO2013169291A3 (en) 2015-06-18
KR20150027081A (ko) 2015-03-11
MX2014013503A (es) 2015-11-13
CA2872623A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
ZA201400611B (en) Shelf-monitoring system
ZA201401667B (en) Tilling apparatus
PT2699293T (pt) Aparelho de autoinjeção
EP2776126A4 (en) DEFINITION OF EFFECTIVE DEFIBRILLATION
EP2719500A4 (en) PART PROCESSING SYSTEM
GB2491044B (en) Ablutionary system
GB201117295D0 (en) Compressible dressing
SG11201505152PA (en) Method for inducing astrocytes
GB201202599D0 (en) Beleuchtungseinrichtung fur fahrzeuge
ZA201401657B (en) Pimping system
GB2494309A9 (en) Wheelchair system
EP2726009A4 (en) MEDICAL MANIPULATOR SYSTEM
GB201107790D0 (en) Medical simulation system
IL228700A0 (en) A method for modulating cytokine activity
PL2741811T3 (pl) Układ do leczenia objawów
GB2533507B (en) Cultivator
EP2700820A4 (en) ENGINE ATTACHMENT SYSTEM
PT2719842E (pt) Reforço para utilização estrutural
GB201112887D0 (en) Device for penetrating skin
GB201119151D0 (en) Gait improvement system
GB201202500D0 (en) Frame system
GB201109708D0 (en) Compliance system
GB201121144D0 (en) Incubators
GB201100792D0 (en) Incubators
GB201110257D0 (en) Activity monitoring system